Nanomolar E-selectin inhibitors: 700-fold potentiation of affinity by multivalent ligand presentation.
Thoma
G
G
Novartis Pharma, AG CH-4002 Basel, Switzerland.
Duthaler
R O
RO
Magnani
J L
JL
Patton
J T
JT
D002240:Carbohydrate Sequence; D019040:E-Selectin / Q000378:metabolism / Q000502:physiology*; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects; D006801:Humans; D008024:Ligands; D008969:Molecular Sequence Data; D009504:Neutrophils / Q000166:cytology / Q000187:drug effects; D009844:Oligosaccharides / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D011107:Polylysine / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology; D000080506:Sialyl Lewis X Antigen
D019040:E-Selectin; D008024:Ligands; D009844:Oligosaccharides; D000080506:Sialyl Lewis X Antigen; D011107:Polylysine